

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	NA

## Non-Preferred Long-Acting Insulin

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comments	Quantity Limit
Basaglar (insulin glargine)	Preferred	May be subject to quantity limit
Lantus (insulin glargine) Levemir (insulin detemir) Semglee (insulin glargine) Toujeo (insulin glargine) Tresiba (insulin degludec)	Non-Preferred	

### APPROVAL CRITERIA

Requests for a non-preferred long-acting insulin may be approved when the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to Basaglar; **OR**
- II. The preferred agent is not acceptable due to concomitant clinical situations, such as but not limited to:
  - A. Individual is pregnant or intending to become pregnant, and the request is for Levemir.

### Key References:

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes - 2019. Diabetes Care. 2019;42: S90-S102.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 12, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Garber AJ, Abrahamson MJ, Barzilay JI, et. al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocrine Practice. 2019;25:69-100.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

<b>Market Applicability</b>						
<b>Market</b>	<b>GA</b>	<b>KY</b>	<b>MD</b>	<b>NJ</b>	<b>NY</b>	<b>WA</b>
<b>Applicable</b>	X	X	X	X	X	NA

6. McCulloch DK. General principles of insulin therapy in diabetes mellitus. Last updated: September 20, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 28, 2019.
7. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: October 12, 2019.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.